John Lunger
Corporate Officer/Principal chez ADAPTIMMUNE THERAPEUTICS PLC
Fortune : 227 614 $ au 31/03/2024
Profil
John Lunger is currently the Chief Patient Supply Officer at Adaptimmune Therapeutics Plc.
He previously worked as an Independent Director at Genocea Biosciences, Inc. and as the Head-Supply Chain & Commercial Product Supply at Merrimack Pharmaceuticals, Inc. Mr. Lunger completed his undergraduate degree at the United States Naval Academy and holds an MBA from The University of Chicago Booth School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/04/2024 | 816 936 ( 0,14% ) | 215 173 $ | 31/03/2024 | |
| 12/01/2024 | 7 874 ( 0,00% ) | 12 441 $ | 31/03/2024 |
Postes actifs de John Lunger
| Sociétés | Poste | Début |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Corporate Officer/Principal | 01/03/2017 |
Anciens postes connus de John Lunger
| Sociétés | Poste | Fin |
|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| GENOCEA BIOSCIENCES, INC. | Director/Board Member | - |
Formation de John Lunger
| United States Naval Academy | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
